Total Payments
$220,988
2024 Payments
$140,802
Companies
24
Transactions
124
Medicare Patients
1,247
Medicare Billing
$214,613
Payment Breakdown by Category
Research$129,530 (58.6%)
Consulting$48,638 (22.0%)
Travel$18,660 (8.4%)
Other$17,561 (7.9%)
Food & Beverage$4,587 (2.1%)
Education$2,012 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $129,530 | 9 | 58.6% |
| Consulting Fee | $48,638 | 17 | 22.0% |
| Travel and Lodging | $18,660 | 30 | 8.4% |
| Honoraria | $9,200 | 2 | 4.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,361 | 4 | 3.8% |
| Food and Beverage | $4,587 | 60 | 2.1% |
| Education | $2,012 | 2 | 0.9% |
Payments by Type
Research
$129,530
9 transactions
General
$91,458
115 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $128,602 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $34,674 | 39 | $0 (2024) |
| Ascendis Pharma Inc | $15,635 | 9 | $0 (2023) |
| Immunocore Limited | $9,243 | 6 | $0 (2024) |
| Shionogi Inc | $5,990 | 4 | $0 (2021) |
| Incyte Corporation | $5,114 | 11 | $0 (2017) |
| TriSalus Life Sciences, Inc. | $4,527 | 4 | $0 (2024) |
| TESARO, Inc. | $3,718 | 10 | $0 (2019) |
| GENZYME CORPORATION | $3,245 | 1 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $2,480 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140,802 | 31 | IGI Inc ($128,602) |
| 2023 | $39,809 | 30 | Merck Sharp & Dohme LLC ($21,714) |
| 2022 | $13,375 | 8 | Merck Sharp & Dohme LLC ($3,820) |
| 2021 | $6,091 | 5 | Shionogi Inc ($3,510) |
| 2020 | $2,533 | 3 | Shionogi Inc ($2,480) |
| 2019 | $873.39 | 9 | E.R. Squibb & Sons, L.L.C. ($405.29) |
| 2018 | $11,897 | 22 | Merck Sharp & Dohme Corporation ($7,576) |
| 2017 | $5,608 | 16 | Incyte Corporation ($5,114) |
All Payment Transactions
124 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | IGI Inc | — | — | Cash or cash equivalent | $7,175.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $7,429.70 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $4,860.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/06/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Oncology | ||||||
| 11/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.11 | General |
| 10/17/2024 | Delcath Systems | HEPZATO KIT (Drug) | Food and Beverage | Cash or cash equivalent | $124.77 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $8.75 | General |
| Category: Oncology | ||||||
| 08/28/2024 | IGI Inc | — | — | Cash or cash equivalent | $66,867.30 | Research |
| Study: GRC 54276-101 | ||||||
| 06/26/2024 | Immunocore Limited | — | Honoraria | Cash or cash equivalent | $6,400.00 | General |
| 06/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $45.26 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2024 | TriSalus Life Sciences, Inc. | TRINAV INFUSION SYSTEM (Device) | Food and Beverage | In-kind items and services | $301.49 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2024 | TriSalus Life Sciences, Inc. | TRINAV INFUSION SYSTEM (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $30.09 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $8.53 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $191.32 | General |
| Category: VACCINE | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $114.44 | General |
| Category: VACCINE | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $64.00 | General |
| Category: VACCINE | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | Cash or cash equivalent | $10.31 | General |
| Category: VACCINE | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $348.71 | General |
| Category: VACCINE | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $297.08 | General |
| Category: VACCINE | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $129.99 | General |
| Category: VACCINE | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | Cash or cash equivalent | $100.04 | General |
| Category: VACCINE | ||||||
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $39.98 | General |
| Category: VACCINE | ||||||
| 04/09/2024 | Immunocore Limited | KIMMTRAK (Drug) | Honoraria | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $536.53 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GRC 54276-101 | IGI Inc | $128,602 | 5 |
| A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | Regeneron Pharmaceuticals, Inc. | $536.53 | 1 |
| A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | Regeneron Pharmaceuticals, Inc. | $231.71 | 1 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| Phase 1 2a First In Human Study of BMS 986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 313 | 514 | $131,402 | $51,404 |
| 2022 | 6 | 286 | 538 | $137,563 | $54,710 |
| 2021 | 6 | 363 | 585 | $153,243 | $60,779 |
| 2020 | 5 | 285 | 568 | $141,203 | $47,720 |
Total Patients
1,247
Total Services
2,205
Medicare Billing
$214,613
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 165 | 301 | $77,056 | $31,530 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 52 | 52 | $18,824 | $6,713 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 87 | $16,356 | $6,374 | 39.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 60 | $15,540 | $5,544 | 35.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 14 | $3,626 | $1,242 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 152 | 310 | $79,360 | $33,815 | 42.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 107 | $27,713 | $8,590 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $16,652 | $6,436 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 45 | $8,528 | $3,492 | 40.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 15 | $3,885 | $1,235 | 31.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 15 | $1,425 | $1,142 | 80.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 148 | 273 | $69,976 | $30,776 | 44.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 70 | 70 | $25,340 | $10,090 | 39.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 79 | 112 | $21,124 | $8,375 | 39.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 92 | $23,828 | $7,514 | 31.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 20 | 25 | $6,475 | $2,013 | 31.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $6,500 | $2,011 | 30.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 129 | 299 | $75,339 | $25,771 | 34.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 32 | 89 | $23,051 | $7,438 | 32.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 58 | 114 | $21,290 | $6,867 | 32.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 43 | 43 | $15,566 | $5,657 | 36.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 23 | 23 | $5,957 | $1,987 | 33.4% |
About Diwakar Davar
Diwakar Davar is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2009. The National Provider Identifier (NPI) number assigned to this provider is 1295965523.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Diwakar Davar has received a total of $220,988 in payments from pharmaceutical and medical device companies, with $140,802 received in 2024. These payments were reported across 124 transactions from 24 companies. The most common payment nature is "" ($129,530).
As a Medicare-enrolled provider, Davar has provided services to 1,247 Medicare beneficiaries, totaling 2,205 services with total Medicare billing of $214,613. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 07/21/2009
- Last Updated 05/24/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1295965523
Products in Payments
- TRINAV INFUSION SYSTEM (Device) $4,527
- LIBTAYO (Biological) $3,294
- KIMMTRAK (Drug) $2,843
- Lenvima (Drug) $1,785
- Proleukin (Drug) $493.61
- KEYTRUDA (Biological) $405.05
- Amtagvi (Drug) $274.24
- OPDIVO (Biological) $192.06
- HEPZATO KIT (Drug) $124.77
- IMLYGIC (Biological) $95.58
- ZEJULA (Drug) $76.35
- MEKINIST (Drug) $62.21
- BRAFTOVI (Drug) $55.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360